6-(2,4-difluorophenoxy)-2-methanesulfonyl-8-(1-methanesulfonylpiperidin-4-yl)-8H-pyrido[2,3-d]pyrimidin-7-one | 1280218-53-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-(2,4-difluorophenoxy)-2-methanesulfonyl-8-(1-methanesulfonylpiperidin-4-yl)-8H-pyrido[2,3-d]pyrimidin-7-one
• 英文别名: 6-(2,4-Difluorophenoxy)-2-methylsulfonyl-8-(1-methylsulfonylpiperidin-4-yl)pyrido[2,3-d]pyrimidin-7-one
• CAS: 1280218-53-2
• 化学式: C₂₀H₂₀F₂N₄O₆S₂
• 分子量: 514.531
• InChiKey: BLSSSMXTSJFZMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  144
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  4-氨基四氢吡喃 、 6-(2,4-difluorophenoxy)-2-methanesulfonyl-8-(1-methanesulfonylpiperidin-4-yl)-8H-pyrido[2,3-d]pyrimidin-7-one 以 N-甲基吡咯烷酮 为溶剂， 反应 7.0h， 以0.073 g的产率得到6-(2,4-difluorophenoxy)-8-(1-methanesulfonylpiperidin-4-yl)-2-(tetrahydropyran-4-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

  摘要：

  The development of a new series of p38 alpha inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38a, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

  DOI：

  10.1021/jm101423y
• 作为产物：
  描述：

  1-甲磺酰基-4-氨基哌啶 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 potassium carbonate 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 6-(2,4-difluorophenoxy)-2-methanesulfonyl-8-(1-methanesulfonylpiperidin-4-yl)-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

  摘要：

  The development of a new series of p38 alpha inhibitors resulted in the identification of two clinical candidates, one of which was advanced into a phase 2 clinical study for rheumatoid arthritis. The original lead, an lck inhibitor that also potently inhibited p38a, was a screening hit from our kinase inhibitor library. This manuscript describes the optimization of the lead to p38-selective examples with good pharmacokinetic properties.

  DOI：

  10.1021/jm101423y